Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach

In continuation of our endeavors to develop new, potent, selective, and less toxic anti-HIV agents, we describe our structure-based bioisosterism design, synthetic strategy, and structure–activity relationship (SAR) studies that led to the identification of pyridazinylthioacetamides, a novel class of NNRTIs, isosteres of arylazolylthioacetanilide derivatives. Nearly all of the tested compounds inhibited HIV-1 strain IIIB replication in the lower micromolar concentration range (EC50: 0.046–5.46 μM). Notably, the most promising compound 8k exhibited extremely potent inhibitory activity against HIV-1 replication with an EC50 value of 0.046 μM, CC50 of 99.9 μM and the viral selectivity index amounted to 2149. These values were much better than those of NVP (EC50 = 0.09 μM) and DDC (EC50 = 1.04 μM). Compound 8k also exhibited moderate inhibition of enzymatic activity with an IC50 value of 4.06 μM, which was of the same order of magnitude as that of NVP (2.74 μM). Docking calculations were also performed to investigate the binding mode of compound 8k into the non-nucleoside binding site of HIV-1 RT and to rationalize some SARs.

[1]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design. , 1996, Chemical reviews.

[2]  E. Clercq.  Human viral diseases: what is next for antiviral drug discovery? , 2012 .

[3]  E. De Clercq,et al.  Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. , 2011, European journal of medicinal chemistry.

[4]  Peng Zhan,et al.  HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design , 2013, Medicinal research reviews.

[5]  A. Rieger,et al.  Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve Subjects , 2010, Antimicrobial Agents and Chemotherapy.

[6]  E. De Clercq,et al.  Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2009, European journal of medicinal chemistry.

[7]  C. Pannecouque,et al.  1,2,3‐Thiadiazole Thioacetanilides. Part 2 , 2010, Chemistry & biodiversity.

[8]  E. De Clercq,et al.  1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. , 2009, Bioorganic & medicinal chemistry.

[9]  Zengjun Fang,et al.  Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. , 2009, Bioorganic & Medicinal Chemistry.

[10]  Peng Zhan,et al.  Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. , 2009, Current medicinal chemistry.

[11]  Y. Ohtsuki,et al.  Type C Virus-Producing Cell Lines Derived from Adult T Cell Leukemia , 1982 .

[12]  E. De Clercq,et al.  1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[13]  L. M. Lima,et al.  Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.

[14]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[15]  K. Kuhen,et al.  Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[16]  E. De Clercq,et al.  Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents , 2012, Archives of Pharmacal Research.

[17]  P. Bonneau,et al.  Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[18]  E. Clercq,et al.  Antivirals: past, present and future. , 2013, Biochemical pharmacology.

[19]  J. Duan,et al.  Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. , 2007, Bioorganic & medicinal chemistry letters.

[20]  Michael Rowley,et al.  Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. , 2006, Bioorganic & medicinal chemistry letters.

[21]  E. De Clercq,et al.  Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs. , 2007, Molecules.

[22]  R. Steigbigel,et al.  Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase. , 1993, Journal of virological methods.

[23]  Zengjun Fang,et al.  Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2009, Bioorganic & medicinal chemistry.

[24]  Peng Zhan,et al.  Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. , 2009, Mini reviews in medicinal chemistry.

[25]  K. Varani,et al.  N6-[(Hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5′-N-ethylcarboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A2B adenosine receptor , 2007 .

[26]  D. Jayaweera,et al.  New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data , 2012, Expert opinion on pharmacotherapy.

[27]  Peng Zhan,et al.  Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. , 2012, Journal of medicinal chemistry.

[28]  C. Pannecouque,et al.  Synthesis and anti-HIV activity evaluation of novel N′-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides , 2010, Medicinal Chemistry Research.

[29]  C. Pannecouque,et al.  Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later , 2008, Nature Protocols.

[30]  Hongyu Zhao,et al.  Medicinal chemistry strategies in follow-on drug discovery. , 2009, Drug discovery today.

[31]  A. M. Roe,et al.  Preparation and some reactions of 4- and 5-aryl-4,5-dihydropyridazin-3(2H)-ones , 1985 .

[32]  Peng Zhan,et al.  Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 – 2010) , 2011, Expert opinion on therapeutic patents.

[33]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[34]  P. Bonneau,et al.  Investigation on the role of the tetrazole in the binding of thiotetrazolylacetanilides with HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. , 2009, Bioorganic & medicinal chemistry letters.

[35]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.

[36]  M. Allan,et al.  Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[37]  Olesen Ph,et al.  The use of bioisosteric groups in lead optimization. , 2001 .

[38]  Peng Zhan,et al.  Design strategies of novel NNRTIs to overcome drug resistance. , 2009, Current medicinal chemistry.